Biovex

Formed in 1999, Biovex is a private biotech company, based near Oxford, developing a new class of potent vaccines to treat and prevent cancer and certain viral diseases. The company has two vaccine platforms; OncoVEX and ImmunoVEX, and a functional genomics platform for gene target validation in neurons and other tissues (NeuroVEX). The Company`s lead product has completed Phase I clinical trials with Phase II studies in melanoma, breast cancer and head and neck cancer begun in October 2006. UCLB are delighted to announce that US biotechnology giant Amgen acquired Biovex in February 2011.